blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2736896

EP2736896 - 3-OXO-2,3-DIHYDRO-1H-INDAZOLE-4-CARBOXAMIDE DERIVATIVES AS PARP-1 INHIBITORS [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  20.10.2017
Database last updated on 14.09.2024
FormerThe patent has been granted
Status updated on  11.11.2016
FormerGrant of patent is intended
Status updated on  07.11.2016
Most recent event   Tooltip17.07.2020Lapse of the patent in a contracting state
New state(s): AL		published on 19.08.2020  [2020/34]
Applicant(s)For all designated states
Nerviano Medical Sciences S.r.l.
Viale Pasteur, 10 P.O. Box 11
20014 Nerviano (MI) / IT
[2014/23]
Inventor(s)01 / PAPEO, Gianluca Mariano Enrico
Via Monza 38
I-23870 Cernusco Lombardone (LC) / IT
02 / BORGHI, Daniela
P.O.Box N.11
Viale Pasteur 10
I-20014 Nerviano (Milan) / IT
03 / CARUSO, Michele
Via Desiderio 3
I-20131 Milan / IT
04 / POSTERI, Helena
Via Faraona 49/C1
I-21028 Travedona Monate (VA) / IT
05 / KRASAVIN, Mikhail Yurievitch
Institute of Chemistry
St. Petersburg State University
26 Universitetsky Prospekt
Peterhof 198504 / RU
 [2016/34]
Former [2014/23]01 / PAPEO, Gianluca Mariano Enrico
Via Monza 38
I-23870 Cernusco Lombardone (LC) / IT
02 / BORGHI, Daniela
P.O.Box N.11
Viale Pasteur 10
I-20014 Nerviano (Milan) / IT
03 / CARUSO, Michele
Via Desiderio 3
I-20131 Milan / IT
04 / POSTERI, Helena
Via Faraona 49/C1
I-21028 Travedona Monate (VA) / IT
05 / KRASAVIN, Mikhail Yurievitch
Eskitis Institute for Cell and Molecular Therapies
Brisbane Innovation Park
Don Young Road
Nathan, Queensland 4111 / AU
Application number, filing date12737279.518.07.2012
[2016/50]
WO2012EP64054
Priority number, dateEP2011017535526.07.2011         Original published format: EP 11175355
EP2012016733609.05.2012         Original published format: EP 12167336
[2014/23]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2013014038
Date:31.01.2013
Language:EN
[2013/05]
Type: A1 Application with search report 
No.:EP2736896
Date:04.06.2014
Language:EN
The application published by WIPO in one of the EPO official languages on 31.01.2013 takes the place of the publication of the European patent application.
[2014/23]
Type: B1 Patent specification 
No.:EP2736896
Date:14.12.2016
Language:EN
[2016/50]
Search report(s)International search report - published on:EP31.01.2013
ClassificationIPC:C07D401/04, C07D401/10, C07D401/14, C07D403/04, C07D405/14, C07D409/14, A61K31/454, A61K31/4545, A61K31/4439, A61P35/00, A61P9/00, A61P25/00, A61P29/02
[2014/23]
CPC:
C07D401/04 (EP,US); A61K31/4188 (EP,US); A61K31/454 (EP,US);
A61P25/00 (EP); A61P29/02 (EP); A61P35/00 (EP);
A61P43/00 (EP); A61P9/00 (EP); C07D401/10 (EP,US);
C07D401/14 (EP,US); C07D403/04 (EP,US); C07D405/14 (EP,US);
C07D409/14 (EP,US) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2014/23]
Extension statesBANot yet paid
MENot yet paid
TitleGerman:3-OXO-2,3-DIHYDRO-1H-INDAZOLE-4-CARBOXAMIDE DERIVATE ALS PARP-1 INHIBITOREN[2016/19]
English:3-OXO-2,3-DIHYDRO-1H-INDAZOLE-4-CARBOXAMIDE DERIVATIVES AS PARP-1 INHIBITORS[2014/23]
French:DÉRIVÉS DE 3-OXO-2,3-DIHYDRO-1H-INDAZOLE-4-CARBOXAMIDE EN TANT QU'INHIBITEURS DE PARP-1[2016/19]
Former [2014/23]3-OXO-2,3-DIHYDRO-1H-INDAZOL-4-CARBOXAMIDDERIVATE ALS PARP-1-INHIBITOREN
Former [2014/23]DÉRIVÉS DE 3-OXO-2,3-DIHYDRO-1H-INDAZOLE-4-CARBOXAMIDE UTILISÉS COMME INHIBITEURS DE LA PARP-1
Entry into regional phase20.02.2014National basic fee paid 
20.02.2014Designation fee(s) paid 
20.02.2014Examination fee paid 
Examination procedure20.02.2014Amendment by applicant (claims and/or description)
20.02.2014Examination requested  [2014/23]
04.08.2015Despatch of a communication from the examining division (Time limit: M04)
17.11.2015Reply to a communication from the examining division
03.05.2016Communication of intention to grant the patent
15.07.2016Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO
04.08.2016Communication of intention to grant the patent
04.11.2016Fee for grant paid
04.11.2016Fee for publishing/printing paid
04.11.2016Receipt of the translation of the claim(s)
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  04.08.2015
Opposition(s)15.09.2017No opposition filed within time limit [2017/47]
Fees paidRenewal fee
26.11.2014Renewal fee patent year 03
27.07.2015Renewal fee patent year 04
27.07.2016Renewal fee patent year 05
Penalty fee
Additional fee for renewal fee
31.07.201403   M06   Fee paid on   26.11.2014
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU18.07.2012
AL14.12.2016
AT14.12.2016
BE14.12.2016
CY14.12.2016
CZ14.12.2016
DK14.12.2016
EE14.12.2016
FI14.12.2016
HR14.12.2016
LT14.12.2016
LV14.12.2016
MC14.12.2016
MK14.12.2016
NL14.12.2016
PL14.12.2016
RO14.12.2016
RS14.12.2016
SE14.12.2016
SI14.12.2016
SK14.12.2016
SM14.12.2016
TR14.12.2016
BG14.03.2017
NO14.03.2017
GR15.03.2017
IS14.04.2017
PT14.04.2017
LU18.07.2017
MT18.07.2017
[2020/34]
Former [2020/15]HU18.07.2012
AT14.12.2016
BE14.12.2016
CY14.12.2016
CZ14.12.2016
DK14.12.2016
EE14.12.2016
FI14.12.2016
HR14.12.2016
LT14.12.2016
LV14.12.2016
MC14.12.2016
MK14.12.2016
NL14.12.2016
PL14.12.2016
RO14.12.2016
RS14.12.2016
SE14.12.2016
SI14.12.2016
SK14.12.2016
SM14.12.2016
TR14.12.2016
BG14.03.2017
NO14.03.2017
GR15.03.2017
IS14.04.2017
PT14.04.2017
LU18.07.2017
MT18.07.2017
Former [2019/51]HU18.07.2012
AT14.12.2016
BE14.12.2016
CY14.12.2016
CZ14.12.2016
DK14.12.2016
EE14.12.2016
FI14.12.2016
HR14.12.2016
LT14.12.2016
LV14.12.2016
MC14.12.2016
MK14.12.2016
NL14.12.2016
PL14.12.2016
RO14.12.2016
RS14.12.2016
SE14.12.2016
SI14.12.2016
SK14.12.2016
SM14.12.2016
BG14.03.2017
NO14.03.2017
GR15.03.2017
IS14.04.2017
PT14.04.2017
LU18.07.2017
MT18.07.2017
Former [2019/46]HU18.07.2012
AT14.12.2016
BE14.12.2016
CY14.12.2016
CZ14.12.2016
DK14.12.2016
EE14.12.2016
FI14.12.2016
HR14.12.2016
LT14.12.2016
LV14.12.2016
MC14.12.2016
NL14.12.2016
PL14.12.2016
RO14.12.2016
RS14.12.2016
SE14.12.2016
SI14.12.2016
SK14.12.2016
SM14.12.2016
BG14.03.2017
NO14.03.2017
GR15.03.2017
IS14.04.2017
PT14.04.2017
LU18.07.2017
MT18.07.2017
Former [2019/31]HU18.07.2012
AT14.12.2016
BE14.12.2016
CZ14.12.2016
DK14.12.2016
EE14.12.2016
FI14.12.2016
HR14.12.2016
LT14.12.2016
LV14.12.2016
MC14.12.2016
NL14.12.2016
PL14.12.2016
RO14.12.2016
RS14.12.2016
SE14.12.2016
SI14.12.2016
SK14.12.2016
SM14.12.2016
BG14.03.2017
NO14.03.2017
GR15.03.2017
IS14.04.2017
PT14.04.2017
LU18.07.2017
MT18.07.2017
Former [2019/30]AT14.12.2016
BE14.12.2016
CZ14.12.2016
DK14.12.2016
EE14.12.2016
FI14.12.2016
HR14.12.2016
LT14.12.2016
LV14.12.2016
MC14.12.2016
NL14.12.2016
PL14.12.2016
RO14.12.2016
RS14.12.2016
SE14.12.2016
SI14.12.2016
SK14.12.2016
SM14.12.2016
BG14.03.2017
NO14.03.2017
GR15.03.2017
IS14.04.2017
PT14.04.2017
LU18.07.2017
MT18.07.2017
Former [2018/43]AT14.12.2016
BE14.12.2016
CZ14.12.2016
DK14.12.2016
EE14.12.2016
FI14.12.2016
HR14.12.2016
LT14.12.2016
LV14.12.2016
NL14.12.2016
PL14.12.2016
RO14.12.2016
RS14.12.2016
SE14.12.2016
SI14.12.2016
SK14.12.2016
SM14.12.2016
BG14.03.2017
NO14.03.2017
GR15.03.2017
IS14.04.2017
PT14.04.2017
LU18.07.2017
MT18.07.2017
Former [2018/34]AT14.12.2016
BE14.12.2016
CZ14.12.2016
DK14.12.2016
EE14.12.2016
FI14.12.2016
HR14.12.2016
LT14.12.2016
LV14.12.2016
NL14.12.2016
PL14.12.2016
RO14.12.2016
RS14.12.2016
SE14.12.2016
SI14.12.2016
SK14.12.2016
SM14.12.2016
BG14.03.2017
NO14.03.2017
GR15.03.2017
IS14.04.2017
PT14.04.2017
LU18.07.2017
Former [2018/14]AT14.12.2016
BE14.12.2016
CZ14.12.2016
DK14.12.2016
EE14.12.2016
FI14.12.2016
HR14.12.2016
LT14.12.2016
LV14.12.2016
NL14.12.2016
PL14.12.2016
RO14.12.2016
RS14.12.2016
SE14.12.2016
SI14.12.2016
SK14.12.2016
SM14.12.2016
BG14.03.2017
NO14.03.2017
GR15.03.2017
IS14.04.2017
PT14.04.2017
Former [2018/01]AT14.12.2016
BE14.12.2016
CZ14.12.2016
DK14.12.2016
EE14.12.2016
FI14.12.2016
HR14.12.2016
LT14.12.2016
LV14.12.2016
NL14.12.2016
PL14.12.2016
RO14.12.2016
RS14.12.2016
SE14.12.2016
SK14.12.2016
SM14.12.2016
BG14.03.2017
NO14.03.2017
GR15.03.2017
IS14.04.2017
PT14.04.2017
Former [2017/41]AT14.12.2016
BE14.12.2016
CZ14.12.2016
EE14.12.2016
FI14.12.2016
HR14.12.2016
LT14.12.2016
LV14.12.2016
NL14.12.2016
PL14.12.2016
RO14.12.2016
RS14.12.2016
SE14.12.2016
SK14.12.2016
SM14.12.2016
BG14.03.2017
NO14.03.2017
GR15.03.2017
IS14.04.2017
PT14.04.2017
Former [2017/36]BE14.12.2016
CZ14.12.2016
EE14.12.2016
FI14.12.2016
HR14.12.2016
LT14.12.2016
LV14.12.2016
NL14.12.2016
PL14.12.2016
RO14.12.2016
RS14.12.2016
SE14.12.2016
SK14.12.2016
NO14.03.2017
GR15.03.2017
IS14.04.2017
Former [2017/31]FI14.12.2016
HR14.12.2016
LT14.12.2016
LV14.12.2016
NL14.12.2016
RS14.12.2016
SE14.12.2016
NO14.03.2017
GR15.03.2017
Former [2017/28]FI14.12.2016
HR14.12.2016
LT14.12.2016
LV14.12.2016
RS14.12.2016
SE14.12.2016
NO14.03.2017
GR15.03.2017
Former [2017/12]LV14.12.2016
Cited inInternational search[XD]EP0355970  (ICI PLC [GB], et al) [XD] 1,2,4,5,16,23 * claims 1,2,6,8 *;
 [A]WO2011006803  (NERVIANO MEDICAL SCIENCES SRL [IT], et al) [A] 1-25 * the whole document *;
 [A]WO2007041357  (ABBOTT LAB [US], et al) [A] 1-25 * the whole document *;
 [A]WO2008084261  (ANGELETTI P IST RICHERCHE BIO [IT], et al) [A] 1-25 * the whole document *
by applicantWO02100833
 WO2008141385
 EP0355970
 WO2010133647
    - BIOORG. MED. CHEM. LETT., (2007), vol. 17, pages 6572 - 6575
    - J. MED. CHEM., (2010), vol. 53, pages 3517 - 3531
    - BIOORG. MED. CHEM. LETT., (2005), vol. 15, pages 5499 - 5503
    - SIMEONI M. ET AL., CANCER RES, (2004), vol. 64, pages 1094 - 1101
    - ANTICANCER DRUGS, (1996), vol. 7, pages 437 - 460
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.